GlaxoSmithKline to acquire Reliant for €1.1 billion in cash. With the operation, Glaxo acquires the cardiological specialty Lovaza, which allows it to strengthen its presence in the USA in this segment. Sales of cardiovascular specialties accounted for approximately £1.64 billion (of the total £20 billion) of Glaxo's turnover last year. Reliant reported sales of 341 million in the first nine months of 2007 and should contribute to Glaxo's profits as early as 2008. Finanza e Mercati dated 22/11/2007 p. 12
